Search results for "ARTICLES"

showing 10 items of 9626 documents

Cutaneous and Allergic reactions due to COVID‐19 vaccinations: A review

2021

ABSTRACT Introduction The pandemic caused by the novel coronavirus disease 2019 (COVID‐19) has had an unprecedented impact on the overall health and the global economy. Vaccination is currently the most dependable strategy to end the pandemic, despite the slower‐than‐hoped‐for rollout, particularly for low‐to‐middle‐income countries, and the uncertain duration of protection afforded by vaccination. The spike protein of the virus (immunodominant antigen of the virus) is the main target of the approved and candidate SARS‐CoV‐2 vaccines. This protein binds to the ACE2 receptor of the host cell, initiating the entry of the virus into the cell and the chain of subsequent events ending to Acute R…

medicine.medical_specialtyAllergyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)ExacerbationReview ArticleDermatologyallergic reactionsmedicine.disease_causeSARS‐CoV‐2VirusAntigenCOVID‐19PandemicHypersensitivityHumansMedicineIntensive care medicineReview ArticlesCoronavirusbusiness.industryVaccinationCOVID-19cutaneous reactionsmedicine.diseaseVaccinationBNT162b2mRNA VaccinesbusinessJournal of Cosmetic Dermatology
researchProduct

Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells

2012

Zoledronic acid (ZOL) is the most potent nitrogen-containing bisphosphonate (N-BPs) that strongly binds to bone mineral and acts as a powerful inhibitor of bone resorption, already clinically available for the treatment of patients with osteolytic metastases. Recent data also suggest that ZOL, used in breast cancer, may provide more than just supportive care modifying the course of the disease, though the possible molecular mechanism of action is still unclear. As breast cancer is one of the primary tumours with high propensity to metastasize to the bone, we investigated, for the first time, differential gene expression profile on Michigan Cancer Foundation-7 (MCF-7) breast cancer cells tre…

medicine.medical_specialtyAngiogenesismedicine.medical_treatmentBlotting WesternAngiogenesis InhibitorsAntineoplastic AgentsBreast NeoplasmsBiologyReal-Time Polymerase Chain ReactionZoledronic AcidZOL FN1 TGF-b1 THBS-1 invasion breast cancerBone resorptionThrombospondin 1Transforming Growth Factor beta1breast cancerBreast cancerTGF-β1Internal medicineThrombospondin 1medicineHumansBone ResorptionCell ProliferationMatrigelDiphosphonatesFN1Gene Expression ProfilingImidazolesCancerOriginal ArticlesCell BiologyZOLBisphosphonateMicroarray Analysisinvasionmedicine.diseaseFibronectinsUp-RegulationGene Expression Regulation NeoplasticEndocrinologyZoledronic acidTHBS-1MCF-7 CellsCancer researchMolecular MedicineFemalemedicine.drug
researchProduct

Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study

2020

Altres ajuts: This work was supported in part by Fundació La Marató de TV3 (201516-10, 201502-30), Societat Catalana de Cardiologia, "la Caixa" Banking Foundation. Altres ajuts: PERIS/SLT002-16-00234 Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor developed for the treatment of heart failure with reduced ejection fraction. Its benefits are achieved through the inhibition of neprilysin (NEP) and the specific blockade of the angiotensin receptor AT1. The many peptides metabolized by NEP suggest multifaceted potential consequences of its inhibition. We sought to evaluate the short-term changes in serum endorphin (EP) values and their relation with patients' p…

medicine.medical_specialtyAngiotensin receptorEndorphins; Heart failure; Neprilysin; Sacubitril/valsartan; α-Endorphin; γ-Endorphinα‐EndorphinVascular damage Radboud Institute for Health Sciences [Radboudumc 16]HemodynamicsPilot ProjectsHeart failure030204 cardiovascular system & hematologyγ‐EndorphinvalsartanSacubitril03 medical and health sciences0302 clinical medicineOriginal Research ArticlesInternal medicinemedicineHumansDiseases of the circulatory (Cardiovascular) systemalpha-EndorphinOriginal Research ArticleProspective Studies030212 general & internal medicineSacubitril/valsartanγ-EndorphinAngiotensin II receptor type 1Ejection fractionbusiness.industryα-EndorphinStroke Volumegamma-Endorphinmedicine.diseaseSacubitrilValsartanRC666-701Heart failureCardiologyNeprilysinEndorphinsCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drug
researchProduct

Prognostic impact of systolic blood pressure in acute heart failure with preserved ejection fraction in older patients

2021

Abstract Aims Recent guidelines recommend a systolic blood pressure (SBP) target below 130 mmHg in heart failure patients with preserved ejection fraction (HFpEF), whatever their age. We investigated whether this intensive SBP control was associated with better survival in very old adults hospitalized for acute HFpEF. Methods and results We conducted an observational study in an acute geriatric unit: all consecutive patients discharged from hospital for acute heart failure from 1 March 2019 to 29 February 2020 with a diagnosis of HFpEF were included. Re‐hospitalization and all‐cause mortality at 1 year were compared according to the mean SBP at discharge (patients with a mean SBP < 130 mmHg…

medicine.medical_specialtyBlood PressureVentricular Function LeftElderlyInternal medicineRe‐hospitalizationDiseases of the circulatory (Cardiovascular) systemHumansMedicineMortalityMedical prescriptionProspective cohort studyAgedAged 80 and overHeart FailureEjection fractionbusiness.industryHazard ratioStroke VolumeOriginal ArticlesPreserved ejection fractionPrognosismedicine.diseaseConfidence intervalBlood pressureRC666-701Heart failureSystolic blood pressureCardiologyOriginal ArticleCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionESC Heart Failure
researchProduct

Effect of uric acid in animal models of ischemic stroke: A systematic review and meta-analysis

2020

Addition of uric acid (UA) to thrombolytic therapy, although safe, showed limited efficacy in improving patients’ stroke outcome, despite alleged neuroprotective effects of UA in preclinical research. This systematic review assessed the effects of UA on brain structural and functional outcomes in animal models of ischemic stroke. We searched Medline, Embase and Web of Science to identify 16 and 14 eligible rodent studies for qualitative and quantitative synthesis, respectively. Range of evidence met 10 of a possible 13 STAIR criteria. Median (Q1, Q3) quality score was 7.5 (6, 10) on the CAMARADES 15-item checklist. For each outcome, we used standardised mean difference (SMD) as effect size…

medicine.medical_specialtyBrain damageNeuroprotectionMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAnimal modelFibrinolytic AgentsInternal medicineStroke outcomeIschaemic strokeAnimalsHumansMedicineThrombolytic TherapyReview ArticlesIschemic Stroke030304 developmental biology0303 health sciencesbusiness.industryRecovery of FunctionRatsUric AcidNeurologychemistryMeta-analysisIschemic strokeCardiologyUric acidNeurology (clinical)Nervous System Diseasesmedicine.symptomCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryJournal of Cerebral Blood Flow &amp; Metabolism
researchProduct

Factors Associated with Low Body Mass Index in Huntington's Disease: A Spanish Multicenter Study of the European Huntington's Disease Registry

2016

Background Patients with Huntington's disease (HD) are at risk for body weight loss and increased risk for institutionalization, morbidity, and mortality. The aim of this study was to determine the factors associated with low body mass index (BMI) in patients with HD. Methods In this national, observational, cross-sectional study of the European Huntington's Disease Network, the frequency of food consumption, calories, and nutrient intake in patients with HD was assessed using questionnaires validated for the Spanish population and were calculated using the software package Alimentacion and Salud (Diet and Health), version 2.0. Nutritional status was estimated using the BMI, and disease sev…

medicine.medical_specialtyCaloriebusiness.industryDiseaseGene mutationmedicine.disease03 medical and health sciences0302 clinical medicineNeurologyHuntington's diseaseRating scaleInternal medicineLinear regressionmedicinePhysical therapyObservational study030212 general & internal medicineNeurology (clinical)businessBody mass index030217 neurology & neurosurgeryResearch Articles
researchProduct

Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre

2019

BACKGROUND: The recurrence of hepatocellular carcinoma (HCC) is the strongest survival-limiting factor after liver transplantation (LT) in patients with HCC. In the face of donor organ shortage, it is necessary to identify factors associated with HCC recurrence in order to maximize the utility of the available grafts. OBJECTIVE: To study the phenomenon of HCC recurrence after LT at a European transplantation centre over the past 20 years. METHODS: Data from 304 HCC patients who underwent LT were prospectively recorded. Clinical and pathological factors were assessed for their association with recurrence. RESULTS: Fifty-one patients (16.8%) had HCC recurrence after LT. Patients exceeding the…

medicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentEconomic shortageLiver transplantationGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansIn patientneoplasmsProportional Hazards Modelsbusiness.industryLiver NeoplasmsGastroenterologyOriginal Articlesmedicine.diseasePrognosisdigestive system diseasesLiver TransplantationTransplantationEuropeTreatment OutcomeOncology030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm Recurrence LocalbusinessLiver cancer
researchProduct

Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis

2017

Catatonia is an independent syndrome that co-occurs with several mental and medical conditions. We performed a systematic literature review in PubMed/Scopus until February 2017 and meta-analyzed studies reporting catatonia prevalence. Across 74 studies (cross-sectional = 32, longitudinal = 26, retrospective = 16) providing data collected from 1935 to 2017 across all continents, mean catatonia prevalence was 9.0% (k = 80, n = 110 764; 95% CI = 6.9-11.7, I2 = 98%, publication bias P &lt; .01), decreasing to 7.8% (k = 19, n = 7612, 95% CI = 7-8.7, I2 = 38.9%) in a subgroup with low heterogeneity. Catatonia prevalence was 23.9% (k = 8, n = 1168, 95% CI = 10-46.9, I2 = 96%) in patients undergoin…

medicine.medical_specialtyCatatoniaTranstornos Mentaisprevalencemeta-analysiDSM-503 medical and health sciencesDSM5; catatonia; meta-analysis; prevalence; severe mental illness0302 clinical medicineDSM5catatonia meta-analysis DSM5 severe mental illness prevalenceRating scaleInternal medicinesevere mental illnessmedicineHumansMeta-regressionPsychiatryMental DisordersCatatoniaPublication biasmedicine.disease030227 psychiatrymeta-analysisPsychiatry and Mental healthSample size determinationMeta-analysisMajor depressive disordercatatoniaPsychology030217 neurology & neurosurgeryRegular Articles
researchProduct

Unmet needs in the management of pulmonary embolism: catheter-directed therapy looks set to fill the void

2019

medicine.medical_specialtyCatheterbusiness.industrymedicineMEDLINEArticlesCardiology and Cardiovascular MedicineIntensive care medicinemedicine.diseasebusinessThe VoidPulmonary embolismUnmet needsEuropean Heart Journal Supplements
researchProduct

BMP-2 and bFGF release and in vitro effect on human osteoblasts after adsorption to bone grafts and biomaterials.

2012

Objectives Combination of scaffolds and growth factors is a promising option for several clinical problems in bone biomaterials. Simplified growth factor loading by adsorption from aqueous solution is one important option for this technology. We evaluated the adsorption followed by PBS rinsing, release and biological effect of transient loading with basic fibroblast growth factor (bFGF) and bone morphogenic protein 2 (BMP-2) on fresh frozen bone, processed bone matrix, collagen, and a ceramic material with immunofluorescence, enzyme-linked immunosorbent assay (ELISA), and qRT-PCR. Materials and methods The study consisted of three in vitro experiments (immunofluorescence, ELISA, and qRT-PCR…

medicine.medical_specialtyCeramicsTime Factorsmedicine.medical_treatmentBasic fibroblast growth factorOsteocalcinCell Culture TechniquesBone MatrixBone Morphogenetic Protein 2Fluorescent Antibody TechniqueBiocompatible MaterialsCore Binding Factor Alpha 1 SubunitEnzyme-Linked Immunosorbent AssayBone healingMatrix (biology)Bone morphogenetic proteinBone morphogenetic protein 2Bone and Boneschemistry.chemical_compoundmedicineAnimalsHumansCells CulturedOsteoblastsbiologyTissue ScaffoldsReverse Transcriptase Polymerase Chain ReactionGrowth factorOsteoblastAlkaline PhosphataseSurgerymedicine.anatomical_structureDurapatitechemistryDelayed-Action PreparationsOsteocalcinbiology.proteinBiophysicsNanoparticlesFibroblast Growth Factor 2AdsorptionCollagenOral SurgeryBiomarkersClinical oral implants research
researchProduct